Ferdia Therapeutics is a San Diego based, private biotechnology company dedicated to the discovery of best-in-class, long-acting peptide therapeutics suitable for once-daily and/or once-weekly dosing in a patient friendly, multi-use pen device. Our focus is on indications where peptide-based therapeutics have demonstrated clinical efficacy and safety. Using our peptide optimization and half-life extension strategies, our aim is to discover novel, long-acting lead peptides with excellent potency, solubility, and stability, to optimize patient comfort and compliance while expanding efficacy and use in additional indications.
This project aims to develop a long-acting peptide suitable for once-weekly dosing for treatment of age related loss of muscle mass and function. The project is partnered with Vasa Therapeutics. www.vasatherapeutics.com
Two parallel programs focus on developing a peripherally-restricted, long-acting peptide therapeutic as a non-addictive alternatives to opioid treatment for postoperative pain.
Our goal is to develop a best-in-class, once-weekly treatment for children to accelerate bone growth and improve symptoms of achondroplasia.
Our SBS program focuses on developing a best-in-class, once-weekly treatment to reduce the need for intravenous nutrition and fluids in patients with SBS.
Founder and Principle Investigator
Director of Pharmacology
Associate Director of Chemistry
DMPK Consultant
Toxicology Consultant
Operations
December 5, 2021
Ferdia Therapeutics signed a partnership agreement to license a long-acting peptide agonist for the treatment of sarcopenia to Vasa Therapeutics. www.vasatherapeutics.com
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.